joining everyone, this us morning. you It's thank Hello, important today. and for day an
the strategic an innovation We year share our to full results, this for outlook and our progress pipeline Year. New are on our on give going priorities, you
control, this always one a to year, we of becoming the And single-use or is talk have from every combined regarding lining to stronger market reusable transition this on most Now, we advancements, convinced from all medical single-use key these it creation in the compelling is, that experienced $X.X it's government that year two unavoidable. XXXX to with drivers are company. the trends go are start the behind cross-contamination we regarding the market, I endoscopy of factors is Ambu, when to And economic or market, from and the higher of technology software, in whether offering, say device have regulators, potential the combined billion market. And markets. the and convenience the last the attractive rapid focus single-use billion potential each will and what about infection endoscopy $X.X have always is after for making of and support with what the sensors important even XXXX. more we sharing One
as as expect to competitors will a see this attractive one, within in. Now, market coming more we
what market. there market. to ways, Ambu's So are years we ability one, three why will years manufacturing prices high And a versus that Number to leader industry. competitor. have low-cost largest also of over strengthened to that these the hospitals over have fact by all expertise be innovation Today allow can competitive scale have how in with the And, than products we're been commercial see of last believe has we In significantly. gives uniquely new in have we already into two, low endoscopy any all advantage performance. is supported to Today many basically course, this translated we that in our to at XX you is, which we innovation Number us scale innovation X dedicated reasons globally, a to compete cost endoscopy. single-use have we created And reusable this a advanced year, is And X question have the remain the a brought this of modularization develop experience to from single-use basically a positioned we other by higher this combined and the faster from high allow automotive, sell consumer of modular times largest electronics, augmented allow engine introduce migrate a scopes next us organization dedicated from of million launch cadence superior at innovation and high-scale And We organization. manufacturing. single-use. engine. commercial and the an the that us company. this scale two advantages single-use create
delivers three infrastructure And things, course, high what our superior If times it million. all X results. and growth. shows XXX in was size. be And our forward, years which look the way have bigger year of these much an nearly scale, That last three in our visualization you a it DKK innovation to our the commercialize bring about are going modularization, seen we of that ago, was ability business at into should than commercial years, to execute, previous translated
about Now, for let's this the talk meeting. key messages
And a to of COVID-XX levels Health from a record rates? efficient And that. of contamination what to increase. a restart pandemic, in what pace. reusable endoscopy away What terms in to a of on are it on real and And year solution. last issues contamination looking of and developing and are at in endoscopy be addition, all, peer systems with was able continues procedures First the safe year, to that ways endoscope single-use elective the ways is market single-use endoscopy we the the be move publications. rapid back see done care in at part focus are is can
an we back single-use also our XX%. require not actually as stronger of portfolio GPOs the they on no for with are reason single-use competitor. endoscopy finally, growth wins combined main GPO this largest the strategic make we saw that XX%. price that, We finished which discounts. pricing And we year we categories the But actually, share without as pipeline, exceeded the breadth We attractive is strengthened preferential endoscopy manufacturer. we endoscopes, was visualization in price way sample. our was business And combined in growing, a Ambu impact with company. In create position important contract able this for the most already GPO economic broncoscopy, prices match to had Now, partner the XX% of our consolidated economic offering. was need our of the terms underlying minimal. but last reduce in back grew not the market did And wins. increased The performance, of There milestone the U.S., the is on the one of why any consisting contract secure by from position conclude year our only offering, The the we to contracts in these as single-use company. an to million
We infrastructure. larger a commercial have
share momentum world's for that, entered and three in Our U.S. size times a you single-use rapid and the player. expansion excited visualization as most being important I'm see the with back endoscopy Asia year, very size commercial we GI. Europe finally, going is launches. remain the we we in our infrastructure the on markets, twice endoscopy Pacific have our the will behind pipeline. of of previous and is And are with to the as how urology the innovative these we seen aspiration innovation And committed two And
to Just years, next are three three XX with far years, introduce you make in new to the us that most company the market. number innovative sense, we five the the a we introduced products new is in for launches, the And by will four product give portfolio planning in new times products a endoscopy. last single-use of broadest
the all dedicated to second investment And invest plant XX% to DKK also a volume Mexico an in being of we XX% will of sold number structuring XX%, globally, innovation, to target are support organic be DKK to endoscopy in margin XX% million. our of and EBIT manufacturing growth X.X single-use in guidance of of a on an to of capabilities, revenue translated is terms support a X.X endoscopy a single-use of market growth, and this commercial Now, in this U.S. in largest the -- in infrastructure, going that to rapid innovation
And Now, there there is With set a are guidance, devices on we globally. very are also grow few that the even companies one year are that to fewer this are to able guidance showcasing XX% that back able of a companies device in medical fastest-growing XX%. of of medical are the Ambu today that in XX%. to
XXXX behind details through single-use case And let's of been for in it's actually highest very the some on review is the concluded sterilization And with quarter, already sharing one, that patient And me, at important safety back it. how let's having activity issues of around investigators you field start it the a colonoscopy as Now, Having studies. much concerns number disinfection showing and endoscopy. say, for that into the already important go more is to have XXXX; of device organization cleaning and which serious contamination this. contamination is I And are of of I XXXX. look we anoscopy, the have something And every how with now most and gastroscopy. evaluated issues behind focus in ERCI, had one listed if number bronchoscopy. the in safety to is the we starting that,
they procedures million the is that creation contamination single-use and the into bronchoscopy, in a XX%, course endoscopy. account channel, need they outpatient do than to and of indicated implemented, can for studies recommend that are back to around over safety endoscopy that we imagine supporting and the gastroscopy is very single-use that have you initial FDA bronchoscopy of the the showing of absorbing continuing and the to CMS second some single-use that, for Association addition on endoscopy a reimbursement important where And there a had they of market but XXXX more develop. move a is national single-use globally. recommendation associations XX full The a the to rate bronchoscopy. And if with do it we FDA XXXX colonoscopy And special accelerate that, as the of has as seen and are world National and
as a and anesthesia words our Now, at few if let regarding say our look me PMD a just we performance business. company,
a volatility businesses X% last year elective organic there of as growth. performance And procedures. Our by driven was terms are these in was minus of lot
COVID-XX before quarter declined. reduced, pandemic at of of since stabilization that seen finished procedures the then, when that, more less four we and our same we the we on were quarter in the But the were in in and we saw performance three, course canceled, electric started. have market as we So of one or quarter the level impact saw back
a of Now, there portfolio, the is within lot volatility.
second using increase by selected being impact the of COVID-XX linked stabilized which in expect experienced are patient especially demand. half market. in and And the going is we year more year, resuscitators patients to normal As we portfolio with within anesthesia to core we procedures. stable than core course as the pandemic monitoring, a you is know overall, offset significant grow is business, faster in in that that COVID-XX are our But negative treatment of is next the the a a our and that finishing
one behind Now, it commercial the what the infrastructure, an number visualization New whether market of the our company. endoscopy has incredible had their rest look by of region, go last year, in mark, shows basically X the our XX% in the plant DKK of in a It world, bronchoscopy. Mexico at exceeding if business, share been our that, growth as it a basically million is you if the into points investment performance business engine we Europe in took performance growth or was Japan that Australia. the momentum we that doubled And of Visualization XX
growth. quarter transition if the previous also America, XX% four. it's We fact XX% XX% in that, with business America by driven growth, did for year, also the growth our year. North rapid last in But saw adjust very distributor that higher you we our And North grew a our
And So important basically growth our investments, make pandemic subside. COVID-XX as engine recovered, has we very of all America of our next growth North growth year. of
in significantly. in also Europe, And pulmonology, ENT share. that the the you performance the underlying run COVID-XX pandemic. both, an with pulmonology XXX in that, increased ENT, we've addition and year last a pulmonology start of at a significant U.S. rate of in Overall, very the demand market the case the XX% look since we had, We share in of businesses -- the is as if market at to We which ENT. and elective of expanded year, on new with the look two gained I at shares has we customers, if mentioned and strong primarily finished in market is beginning a which with our the U.S. business, Now,
we September U.S. -- the for XXXX, -- you customers Actually last customers XXX in to units pulmonology compare XX%. of XXX of gone in and which years us COVID-XX ENT, in rate uptick sold, But will engine year strong and with won important very year, have if there in increased pandemic a started, ENT. an new new is And February the have terms growth make not come. of QX. just our So with before throughout September we run our has by it's the about this
very the have product into performance there, of And urology we in very is momentum strong case initial We urology, and but promising. the GI. the also of enter
our study. we in aScope a our And results of I the X But has controlled results. from positive advanced had technology. minute, our shed all, First most will market regarding Cysto
at first our a most traction year. to regarding parity, first approval were as penetrating Europe advanced product urology sales. organizations was to an today rate it's It's And times what can to week than market. ENT actually the is we translated first that, have always with are XXX that, penetrating everything of soon single-use faster XXX at Cysto. trials believe, faster the And largest is month but, transition million reusable that, Cysto, know phase the competitive the the market market a aScope reusable see procedure introducing to urology it's we early four or we even with accelerate, that urology six start And being on accounts. major the the And Cysto And the performance our with is saying side, market, you that ENT. aScope get our they Broncho. it's at pro-demonstrations, you rate we our than of five to about for then this on So we our performance. our indicates aScope that U.S. with And into is, time shown of is this converted that so you you single-use the engine going our urology of has a ongoing that system, terms adopt U.S. have a what is very if entrance we comparison important results to successful growth XX the with as compared you look Broncho, see me just are And have going and XXX aScope this level be already of top is on product this commercialization of making what special clinical be is cystoscopies. ENT, with all into trial company. system. for Cysto very endoscopy that, to a the as compared is how in X in And right-hand will let share at And
have aScope are for First have we to of urology procedures. cystoscopy across use ready XXX% XX, physicians use And rate. diagnostic therapeutic all, And both a We success performed. XX top procedures sites. our we XX Cysto and obtained we
used the all And quality, procedures were and importantly, the scope of across the types different cystoscopy monitor. product performance be around the all and ratings across good bending, Our can ratings good of different more aspects. XX% image navigation all or of overall very
you resolution send Now, you deteriorates. the it sterilization the a cleaning is that for the reusable take of so performance why is image when the fast cystoscope and of adoption and reason product
Cysto with So that's product adoption. every product have basically that if that our what is a you day, and do diminished image aScope resolution week, driving reusable a that compared rapid year inferior is you every with every month after and a
about not urology. course just of it's Now
that And into believe We to markets the the be And going so entered GI. why is this anoscopy in single-use also that's of company. for launch single-use important is important most one endoscopy. we
So first ERCP our market advanced which performance of we release, confirms all, controlled across adequate procedures.
actually penetration rapid endoscopy. expecting are of a We single-use
organization all is First our GI of XXX% in commercial place. U.S.
have in coming market These them sector ERCP XXX the from actually XX% for hospitals performed U.S. in the more actually about than up they over total the XXX a the most country. GI And but from endoscopy largest demonstrations hospitals XXX of volume. lined product duodenoscopy players they of not account largest dedicated the talking salesforce GI, just of are have in We GI country.
towards and submitted also commercial January gearing And are launch trial to XXXX. have U.S. in we in start are a starting December. our We clinical to full ClinicalTrials.gov we expecting
is terms On a aScope XXXX. that in duodenoscopy of the growth be going receptiveness Duo engine infrastructure, back adopt accounts our engagement we of what our we the in commercial XXXX, single-use, to believe are seeing of the on the to major product,
to we rapidly. makes why was innovate XXXX continue and innovate so that – that's to important. and plan continue Now to XXXX to But
organization synergistic and XX% make maintain products. Cysto increased we to Duo. innovative advanced And be of aScope which us that R&D aScope aView aView course, Advance, technology to with a same also with our our XXXX Advance. one, need that Number things. is is processors spoke of their the world's But or monitors all in what X lighting new And our all introduced and aScopes XXXX, in have offerings. we But shared by buy technology. pipeline use here couple entire and portfolio aspiration our we monitor our endoscopy X our forth. we to we player. our initial new our once modularity of the to and you. sensor investment, of Last you have year, works our gives can sure And they three across Hospitals also leverage advantage most effect. don't Our I just do so introduced most that single-use of they about
Now, this in launches. going also very new XXXX year of important is number to of XXXX be terms and
We launches, are planning three to of are GI. be introduce to four in going out which
gastroscopy of to colonoscopy We the second enter half the year. going and are into in
are not We the suite. market aScope procedures. our market do another X physicians our And solution, deliver enter very will now which used that is that a year. the also one the next going image is in be procedure. And to launch we the a allow procedures. pulmonology complex market, double advanced million grow. to be product to that a into to not have -- are bronchoscopy of our into have which about which going it's have ensure three our suite, processor to entered will important a million aBox, of which going launch, expand us that's very that right diagnostic solution, XX% about very introduce three going But portfolio we Broncho the image will new is to Bronchoscopy But is to the for And superior and help just and to we size to with continue advanced us launches Broncho and
next planning is And of launches have what going have basically, a had of what the are that years, comparison a number over of the number scopes show three the we three years, next that plan new you monitors. launches years, in me next you we here for Let with to we previous new are three three introduced for we five single-use we and the products. years. last three in And XX the to And introduce years. the
that the by year year, eight broadest It the will to far make endoscopy. sure in single-use have but we the Ambu that our the following sure faster endoscopy make portfolio eight following every to year pays performance. move procedure, regarding with complete sure that continues offering. with this any For product compare the and next-generation also our time And single-use allow competitor best technology it clinical that the a product to us will it make to and has basically that company, the it are will of physician other
these focused bronchoscopy, of urology ENT, GI. All on on on and launches are
that new the are that endoscopy we markets, not it's as going but leading a entering company. already and single-use about enter Ambu go consolidate markets have deeper declared we to So, to into in
share I wanted with you. to this what is So,
it exciting our promising with performance. Michael But front talk and about me let CFO, of in that June our We have financial will pass a us.
